NCT04072146View on ClinicalTrials.gov

Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

November 15, 2019

Study Completion Date

November 15, 2019

Conditions
Healthy Subjects
Interventions
DRUG

Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg

Cross over bioavailability study

DRUG

OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg

Cross over bioavailability study

Trial Locations (1)

33136

United States, Miami Florida, Miami

Sponsors
All Listed Sponsors
lead

Oyster Point Pharma, Inc.

INDUSTRY

NCT04072146 - Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline | Biotech Hunter | Biotech Hunter